Drug Trial Radar · NCT00598832
Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%
Last checked: Nov 19, 2026Latest source record: Feb 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,075
Actual
Start
Nov 2007
Primary completion
Oct 2008
Study completion Nov 2008
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Adapalene, 0.1% is safe and effective in the treatment of Acne Vulgaris.
Conditions
- Acne Vulgaris
Interventions
Adapalene lotion 0.1%Drug
Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
Adapalene Lotion VehicleDrug
Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12Time frame: From Baseline to Week 12
- Co-Primary Endpoint: Absolute Change in Total Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
- Co-Primary Endpoint: Absolute Change in Inflammatory Lesion Count From Baseline to Week 12Time frame: Baseline to Week 12
- Co-Primary Endpoint: Absolute Change in NonInflammatory Lesion Counts From Baseline to Week 12Time frame: Baseline to Week 12
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
Burke Pharmaceutical Research
Hot Springs, Arkansas
Scott Dinehart
Little Rock, Arkansas
Dermatology and Laser Center
Marina del Rey, California
Therapeutics Clinical Research
San Diego, California
Solano Clinical Research
Vallejo, California
Colorado Medical Research Center
Denver, Colorado
Longmont Clinic
Longmont, Colorado
Advanced Dermatology
Clermont, Florida
International Dermatology Research, Inc.
Miami, Florida
Anne M. Loebl
Augusta, Georgia
Scott Glazer
Buffalo Grove, Illinois
Sound Bend Clinic
South Bend, Indiana
Hamzavi Dermatology
Port Huron, Michigan
Central Dermatology, PC
St Louis, Missouri
Darmouth-Hitchcock Medical Center Section of Dermatology
Lebanon, New Hampshire
Academic Dermatology
Albuquerque, New Mexico
Elizabeth Arthur
Rochester, New York
Derm Research Center of New York
Stony Brook, New York
Unifour Medical Research Associates
Hickory, North Carolina
Haber Dermatology & Cosmetic Research
South Euclid, Ohio
OU Health Sciences Center-Dept. of Dermatology
Oklahoma City, Oklahoma
Oregon Medical Center, PC
Portland, Oregon
Rivergate Dermatology
Goodlettsville, Tennessee
DermResearch, Inc.
Austin, Texas
Center for Clinical Studies
Houston, Texas
Progressive Clinical Research
San Antonio, Texas
Virginia Clinical Research, Inc.
Norfolk, Virginia
The Dermatology Centre
Calgary, Alberta, Canada
Stratica Medical
Edmonton, Alberta, Canada
Guildford Dermatology Specialists
Surrey, British Columbia, Canada
Dermadvance Research
Winnipeg, Manitoba, Canada
Nexus Clinical Research
St. John's, Newfoundland and Labrador, Canada
Lynderm Research, Inc.
Markham, Ontario, Canada
K. Papp Clinical Research, Inc.
Waterloo, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.